New pages
Jump to navigation
Jump to search
- 18:50, 16 October 2021 Lutetium-177-PSMA-617 (hist | edit) [796 bytes] Jwarner (talk | contribs) (Created page with "==Preliminary data== #'''VISION:''' Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour...")
- 18:40, 21 September 2021 Tisotumab vedotin (Tivdak) (hist | edit) [1,590 bytes] Jwarner (talk | contribs) (Created page with "==Mechanism of action== From the NCI Drug Dictionary: An antibody-drug conjugate (ADC) comprised of a monoclonal antibody against human tissue factor (TF) covalently coupled,...")
- 18:07, 21 September 2021 Medullary thyroid cancer (hist | edit) [15,096 bytes] Jwarner (talk | contribs) (Created page with "Note: these are regimens tested in histology-specific populations, please see the '''main thyroid cancer page''' for other regimens. {| class="wikitable" st...")
- 18:06, 21 September 2021 Differentiated thyroid cancer (hist | edit) [23,977 bytes] Jwarner (talk | contribs) (Created page with "Note: these are regimens tested in histology-specific populations, please see the '''main thyroid cancer page''' for other regimens. {| class="wikitable" st...")
- 12:41, 18 September 2021 Mobocertinib (Exkivity) (hist | edit) [1,551 bytes] Jwarner (talk | contribs) (Created page with "==Mechanism of action== From the NCI Drug Dictionary: An orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineop...")
- 00:12, 3 September 2021 Sorafenib Dosing Nomogram (hist | edit) [3,601 bytes] Cafitts (talk | contribs) (Created page with "{{#lst:Section editor transclusions|peds}} <big>''This page contains studies that were specific to pediatric populations. For the more general AML page, follow Acute myeloid...")
- 21:36, 26 August 2021 Cyclosporine (hist | edit) [4,458 bytes] Jwarner (talk | contribs) (Created page with "'''Note: this page contains information on multiple formulations of cyclosporine.''' ==General information== Class/mechanism: Cyclic polypeptide immunosuppressive agent that r...")
- 13:39, 21 August 2021 Teclistamab (JNJ 64007957) (hist | edit) [1,663 bytes] Jwarner (talk | contribs) (Created page with "==General information== Class/mechanism from the NCI Drug Dictionary: A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell...")
- 16:19, 16 August 2021 Renal cell carcinoma, VHL-associated (hist | edit) [2,135 bytes] Jwarner (talk | contribs) (Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' |- |...")
- 16:09, 16 August 2021 Belzutifan (Welireg) (hist | edit) [1,483 bytes] Jwarner (talk | contribs) (Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/belzutifan NCI Drug Dictionary]: An orally active, small molecule inhibitor...")
- 19:34, 25 July 2021 Ciltacabtagene autoleucel (JNJ-68284528) (hist | edit) [2,015 bytes] Jwarner (talk | contribs) (Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ciltacabtagene-autoleucel NCI Drug Dictionary]: A preparation of autologous...")